Sensyne Health, the UK-based digital health firm, has significantly expanded its data analytics capabilities through a strategic partnership with US clinical trial specialist Phesi, while simultaneously launching a £27.5 million fundraising initiative to accelerate its artificial intelligence (AI) platform development.
The landmark agreement with Phesi will provide Sensyne access to approximately 13.5 million international patient records from 320,000 clinical trials dating back to 2007. This substantial addition complements Sensyne's existing database of 6.1 million UK patient health records, representing about 10% of the British population.
Strategic Investment and Platform Development
The fundraising effort, priced at 90 pence per share, includes plans for a potential additional £2.5 million through an open offer. A significant portion of the proceeds, £10 million, will be used to acquire a 10% equity stake in Phesi, cementing the strategic partnership between the two companies.
The remaining funds will be strategically allocated, with £10 million dedicated to developing Sensight, a real-world pharmaceutical R&D platform designed for rapid and cost-effective data analysis. An additional £6.5 million will support the enhancement of Sense, the company's clinical AI engine serving healthcare providers and payers.
Accelerating Data Analytics Capabilities
Currently, Sensyne faces considerable time constraints in processing data queries, with responses to basic data category questions taking several weeks and clinical AI analyses extending to months. The company's prospectus indicates that the new investments will dramatically reduce these timeframes to seconds for basic queries and weeks for complex analyses.
Collaborative Innovation in Clinical Trials
The five-year collaboration between Sensyne and Phesi will focus on developing innovative solutions combining clinical trial and real-world data. Key initiatives include:
- Creation of "synthetic" clinical trial arms
- Development of advanced clinical decision support tools
- Integration of anonymized clinical trials data with investigator site information
Industry Recognition and Partnerships
Sensyne's data-driven approach has already attracted partnerships with major pharmaceutical companies, including:
- Bayer
- Roche
- Alexion
- Bristol-Myers Squibb
The company's portfolio includes AI-powered digital health applications such as GDm-Health for diabetes management and CVm-Health for COVID-19 monitoring.
The fundraising initiative is being managed by joint bookrunners Peel Hunt and Liberum Capital Limited, marking a significant step in Sensyne's growth trajectory and its mission to transform drug development and clinical research through advanced data analytics.
